Press release
Biosimilar Market Size (US$ 77.1 Billion) | Industry Report 2023-2028
IMARC Group, a leading market research company, has recently releases report titled "Biosimilar Market: Global Industry Trends, Size, Share, Growth, Opportunity and Forecast 2023-2028." The study provides a detailed analysis of the industry, including the global Biosimilar Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.How big is the Biosimilar market?
The global biosimilar market size reached US$ 16.8 Billion in 2022. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market is expected to reach US$ 77.1 Billion by 2028, exhibiting a growth rate (CAGR) of 25.9% during 2023-2028.
Request for a Free PDF Sample of this Report: https://www.imarcgroup.com/biosimilar-market/requestsample
What are Biosimilars services?
Biosimilars are biotherapeutic products that are particularly identical to a reference biologic drug. They are produced using living organisms and cells that have complex molecular structures. To be labeled as a biosimilar, a biological drug must be proved similar in terms of efficacy, safety, and quality. Biosimilars are comparatively more expensive than generic drugs as their production process is complex and requires considerable investments in research and development (R&D) activities.
What are the growth prospects and trends in the Biosimilars industry?
The surging prevalence of chronic diseases, such as cancer and autoimmune diseases, especially among the geriatric population, represents one of the key factors significantly contributing to the market growth. Additionally, the growing instances of patent expiration and loss of protection in several biologic drugs are creating a positive outlook for the market. The manufacturers have to resort to approval from the regulatory authorities once their patent expires to start the production of biosimilars. Moreover, biosimilars do not require extensive marketing, as the efficacy and safety profile of their branded counterparts has already been established, which, in turn, is working in favor of the market growth. Besides this, the high costs related to innovator biologics, especially monoclonal antibodies (mAbs), have compelled governments to undertake initiatives encouraging the usage of biosimilars over branded biologics due to their cost-effectiveness, which is accelerating the market growth.
Checkout Now: https://www.imarcgroup.com/checkout?id=497&method=37
Who are the key players operating in the Biosimilars industry?
The report covers the major market players including:
Novartis
Pfizer
Teva
Celltrion
Merck & Co
Samsung Bioepis
Eli Lilly
Biocon
Reddy's Laboratories
Amgen
Boehringer Ingelheim
What is included in market segmentation?
The report has segmented the market into the following categories:
Molecule insights:
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Indication Insights:
Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Manufacturing Insights:
In-house Manufacturing
Contract Manufacturing
Regional Insights:
United States
Germany
France
Italy
Spain
United Kingdom
Japan
India
South Korea
Others
Inquire Before Buying: https://www.imarcgroup.com/request?type=report&id=497&flag=F
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Market Size (US$ 77.1 Billion) | Industry Report 2023-2028 here
News-ID: 3113622 • Views: …
More Releases from IMARC Group

Automotive Control Cables Manufacturing Plant Setup Report 2025: Machinery, Raw …
Automotive control cables are essential components used to transmit mechanical force in vehicles, enabling the smooth operation of various systems such as brakes, clutches, accelerators, gear shifts, and seating mechanisms. These cables are designed for durability, flexibility, and high performance under diverse driving conditions. Their demand is directly linked to the growth of the automotive industry, aftermarket sales, and increasing consumer preference for enhanced driving comfort and safety.
Setting up an…

Halal Cosmetics Market Size, Trends, Key Players, Opportunity and Forecast 2025- …
IMARC Group, a leading market research company, has recently released a report titled "Halal Cosmetics Market Size, Share, Trends and Forecast by Type, Distribution Channel, and Region, 2025-2033." The study provides a detailed analysis of the industry, including the global halal cosmetics market size, trends, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Halal Cosmetics Market Highlights:
• Halal Cosmetics Market…

Comprehensive Castor Oil Processing Plant Project Report 2025: Setup Guide, Econ …
Castor oil is a versatile vegetable oil extracted from the seeds of the Ricinus communis plant. It is widely used in pharmaceuticals, cosmetics, food processing, lubricants, paints, coatings, and biodiesel production owing to its unique chemical properties, including high ricinoleic acid content. Castor oil derivatives also serve as key raw materials in the polymer, chemical, and industrial sectors.
Establishing a castor oil processing plant involves steps such as seed cleaning, dehulling,…

Honey Processing Plant Report 2025: Capital Investment, Operating Expenses and M …
Honey is a natural sweetener produced by honeybees and is valued for its nutritional, medicinal, and industrial applications. It contains antioxidants, enzymes, vitamins, and minerals that make it a popular ingredient in food and beverages, pharmaceuticals, cosmetics, and personal care products. Processed honey is widely consumed as a sweetener, used in bakery and confectionery items, beverages, dietary supplements, and skincare formulations.
Setting up a honey processing plant involves operations such as…
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…